Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

Cancer Research
Zhi ShiZhe-Sheng Chen

Abstract

It has been reported that gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has the ability to modulate the function of certain ATP-binding cassette (ABC) transporters and to reverse ABC subfamily B member 1 (ABCB1; P-glycoprotein)- and ABC subfamily G member 2 (ABCG2; breast cancer resistance protein/mitoxantrone resistance protein)-mediated multidrug resistance (MDR) in cancer cells. However, it is unknown whether other EGFR TKIs have effects similar to that of gefitinib. In the present study, we have investigated the interaction of another EGFR TKI, erlotinib, with selected ABC drug transporters. Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells. Furthermore, erlotinib did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in all cells and was unable to reverse MRP1-mediated MDR and had no effect on the parental cells. However, erlotinib remarkably inhibited the transport of E(2)17 beta G and methotrexate by ABCG2. In addition, the results of ATPase assays show that erlotinib stimulated the ATPase a...Continue Reading

References

Jan 1, 1992·Annual Review of Cell Biology·C F Higgins
Mar 1, 1985·Somatic Cell and Molecular Genetics·S AkiyamaM M Gottesman
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
Mar 16, 2000·Proceedings of the National Academy of Sciences of the United States of America·Z E Sauna, S V Ambudkar
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Aug 18, 2001·Japanese Journal of Cancer Research : Gann·S AokiM Kobayashi
Jan 30, 2002·Frontiers in Bioscience : a Journal and Virtual Library·Steven GrantPaul Dent
Jun 19, 2003·Journal of the National Cancer Institute·Viktor Grünwald, Manuel Hidalgo
Oct 25, 2003·Oncogene·Suresh V AmbudkarMichael M Gottesman
Oct 25, 2003·Oncogene·Gary D Kruh, Martin G Belinsky
May 25, 2004·Molecular Pharmacology·Csilla Ozvegy-LaczkaBalázs Sarkadi
Oct 20, 2004·Cancer Research·Clinton F StewartPeter J Houghton
Jun 16, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi KitazakiShigeru Kohno
Jul 9, 2005·The Journal of Pharmacology and Experimental Therapeutics·Amit Arora, Eric M Scholar
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 27, 2005·Gene·Nicola NormannoDavid S Salomon
Apr 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T CasconeF Ciardiello
May 3, 2006·Cancer Research·Markos LeggasClinton F Stewart
Dec 6, 2006·Cancer Research·Yanli ZhuangClinton F Stewart
Dec 7, 2006·Journal of the National Cancer Institute·George CusatisSharyn D Baker
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group

❮ Previous
Next ❯

Citations

Jun 6, 2009·Cancer Chemotherapy and Pharmacology·Amalia AzzaritiAngelo Paradiso
May 16, 2013·Cancer Chemotherapy and Pharmacology·Atish PatelZhe-Sheng Chen
Jul 8, 2010·Investigational New Drugs·Gráinne DunneRobert O'Connor
Jan 19, 2008·Pharmaceutical Research·Qingcheng Mao
Mar 1, 2013·European Journal of Drug Metabolism and Pharmacokinetics·C JoveletS Gil
Feb 4, 2011·Cellular Oncology (Dordrecht)·Qing-feng XiangLi-wu Fu
Apr 27, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Xiao-qin ZhaoLi-Wu Fu
Oct 19, 2010·The Journal of Pharmacology and Experimental Therapeutics·Sagar AgarwalWilliam F Elmquist
May 13, 2010·Cancer Research·Angel M CarcabosoClinton F Stewart
Mar 16, 2011·Cancer Research·Zhi ShiZhe-Sheng Chen
Sep 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuiying HuSharyn D Baker
May 11, 2011·Clinical Pharmacokinetics·Matthias SchefflerUwe Fuhr
Jan 13, 2012·Chinese Journal of Cancer·Miao He, Min-Jie Wei
Mar 22, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Fang WangLi-Wu Fu
Jan 30, 2014·Cancer Chemotherapy and Pharmacology·Marta HamiltonBert L Lum
Oct 22, 2010·Investigational New Drugs·Nienke A de VriesOlaf van Tellingen
Oct 10, 2013·Chinese Journal of Cancer·Rishil J KathawalaZhe-Sheng Chen
Mar 15, 2014·International Journal of Oncology·Rishil J KathawalaZhe-Sheng Chen
Dec 14, 2011·Expert Opinion on Therapeutic Targets·Andreas Desiniotis, Natasha Kyprianou
Sep 6, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nagaraju AnreddyZhe-Sheng Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.